BUSINESS
Glenmark Pharma to launch phase 1 trial in solid tumors for GBR 1342
Glenmark Pharmaceuticals is planning to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The decision is driven by recent findings derived…